Ved vurderingen af om Retacrit- terapi er hensigtsmæssig hos cancerpatienter i kemoterapi (risiko for, at patienten transfunderes), bør det tages i betragtning, at der går 2- 3 uger, fra administration af erytropoietin påbegyndes, til der viser sig erytropoietin- fremkaldte røde blodceller.
In cancer patients receiving chemotherapy, the 2-3 week delay between erythropoietin administration and the appearance of erythropoietin-induced red cells should be taken into account when assessing if Retacrit therapy is appropriate (patient at risk of being transfused).